Keyphrases
Overall Survival
56%
Tumor
52%
Breast Cancer
49%
Triple-negative Breast Cancer
44%
Non-small Cell Lung Cancer (NSCLC)
40%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
35%
Neurofibromatosis Type 1 (NF-1)
35%
Confidence Interval
34%
Neurofibromatosis Type I
34%
Multiple Myeloma
32%
Endometrial Cancer
29%
Clinical Trials
28%
Primary Open-angle Glaucoma
25%
Phase II Study
25%
Clinical Outcomes
22%
Acute Myeloid Leukemia
22%
Chemotherapy
22%
Breast Reconstruction
21%
Hazard Ratio
20%
Breast Cancer Patients
19%
Chimeric Antigen Receptor T Cells (CAR-T)
18%
Disease-free Survival
18%
Progression-free Survival
18%
Phase I Study
18%
Risk Factors
18%
Human Breast Cancer
17%
Pancreatic Cancer
17%
Resection
17%
Intraocular Pressure
17%
Multivariate Analysis
17%
Ocular Hypertension
17%
Graft-versus-host Disease (GvHD)
16%
Histology
16%
Neoadjuvant
16%
Prognostic Factors
16%
University of Washington
16%
Alzheimer's Disease
16%
Pathological Complete Response
16%
Adenocarcinoma
15%
Carboplatin
15%
Body Mass Index
15%
Tumor Size
15%
Mastectomy
15%
Granulocyte Colony-stimulating Factor (G-CSF)
14%
Radiation Necrosis
14%
Invasive Breast Cancer
14%
Positive Margins
14%
T Cells
14%
Survival Outcomes
13%
Bevacizumab
13%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
94%
Malignant Neoplasm
55%
Overall Survival
50%
Recurrent Disease
48%
Disease
44%
Uterine Cancer
42%
Surgery
40%
Non Small Cell Lung Cancer
35%
Neurofibromatosis Type I
30%
Triple Negative Breast Cancer
30%
Chemotherapy
26%
Hazard Ratio
21%
Multivariate Analysis
20%
Lymph Node
18%
Cervical Cancer
18%
Biopsy Technique
18%
Gynecological Oncology
17%
Chimeric Antigen Receptor
17%
Adenocarcinoma
16%
Magnetic Resonance Imaging
15%
Prognostic Factor
15%
Hematopoietic Cell
15%
Disease Free Survival
14%
Mastectomy
14%
Randomized Controlled Trial
14%
Radiation Necrosis
14%
Lung Cancer
14%
Fluorine-18
14%
Clinical Trial
13%
Neoadjuvant Chemotherapy
13%
Open Angle Glaucoma
13%
Lymph Duct
13%
Progression Free Survival
13%
Metastatic Carcinoma
12%
Estrogen Receptor
12%
Radiation Therapy
12%
Cytotechnology
12%
Minimal Residual Disease
12%
Ovarian Cancer
12%
Oncology
12%
Surveillance, Epidemiology, and End Results
11%
Sentinel Lymph Node
11%
Multiple Myeloma
11%
Adjuvant Chemotherapy
11%
Sentinel Lymph Node Biopsy
11%
Acute Myeloid Leukemia
11%
Positron Emission Tomography
11%
Kaplan Meier Method
11%
Placebo
11%